Patents by Inventor Andrew M. Scott

Andrew M. Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240117073
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 26, 2023
    Publication date: April 11, 2024
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard C. Nice, Anne Murray, George Mark
  • Patent number: 11160873
    Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: November 2, 2021
    Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd., Olivia Newton-John Cancer Research Institute
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Publication number: 20210032366
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: March 13, 2020
    Publication date: February 4, 2021
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark
  • Publication number: 20190105405
    Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
    Type: Application
    Filed: July 5, 2018
    Publication date: April 11, 2019
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Patent number: 10023653
    Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumor cells and also as a therapeutic agent for treating cancers, tumors and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma and/or melanoma.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 17, 2018
    Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd.
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Publication number: 20180057606
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: July 27, 2017
    Publication date: March 1, 2018
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark
  • Publication number: 20170008976
    Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
    Type: Application
    Filed: February 4, 2015
    Publication date: January 12, 2017
    Inventors: Martin LACKMANN, Peter W. JANES, Lakmali Atapattu MUDIYANSELAGE, Andrew M. SCOTT, Dimitar B. NIKOLOV, Nayanendu SAHA
  • Patent number: 9283276
    Abstract: The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: March 15, 2016
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Terrance Grant Johns, Elizabeth Stockert, Stephen Stockert, Lloyd J. Old, Andrew M. Scott, Veronika M. Rayzman
  • Publication number: 20160046726
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: June 11, 2015
    Publication date: February 18, 2016
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark
  • Publication number: 20140322130
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 30, 2014
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Andrew M. Scott, Terrance Grant Johns, George Mark, Anne Murray, Christoph Renner, Gerd Ritter
  • Patent number: 8848174
    Abstract: A method and corresponding apparatus for coupling an optical beam into a first end of an optical fiber includes two steps. First, light is coupled into a second end of the optical fiber such that an optical reference beam is output from the first end of the optical fiber. Second, at least one beam parameter of the optical beam is matched with the corresponding beam parameter of the optical reference beam. The second step may be performed using a wavefront sensor.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: September 30, 2014
    Assignee: Qinetiq Limited
    Inventors: Andrew M Scott, Andrew J Turner
  • Patent number: 8719140
    Abstract: The claimed invention relates to an adjustable derivative contract. Particularly a method and system for adjusting the derivative contract to account for time value of money due to an occurrence of a corporate event that affects the value of the derivative contract. The claimed method and system allocates distributions amongst different derivative contracts, each derivative contract representing a different economic interest of at least two shares of an underlying security. The claimed invention uses the concepts of present and future values to value derivative contracts in order to more fairly and accurately represent the interests of the various holders of such derivative contracts upon the occurrence of a corporate event affecting the value of these derivative contracts.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: May 6, 2014
    Inventors: Peter A. Broms, Andrew M. Scott
  • Patent number: 8666868
    Abstract: The claimed invention relates to an adjustable derivative contract. Particularly a method and system for adjusting the derivative contract to account for time value of money due to an occurrence of a corporate event that affects the value of the derivative contract. The claimed method and system allocates distributions amongst different derivative contracts, each derivative contract representing a different economic interest of at least two shares of an underlying security. The claimed invention uses the concepts of present and future values to value derivative contracts in order to more fairly and accurately represent the interests of the various holders of such derivative contracts upon the occurrence of a corporate event affecting the value of these derivative contracts.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: March 4, 2014
    Inventors: Peter A. Broms, Andrew M. Scott
  • Patent number: 8447188
    Abstract: A retro-reflective identification tag capable of modulating an optical signal whereby to support bi-directional communication with an associated remote optical interrogation device. The tag comprises a MOEMS modulating layer over a retro-reflective substrate, giving the tag a wide angle of effective operation. The tag modulator may optionally be switched on only responsive to detection of a precursor beam from the interrogation system in order to save power. The interrogation device may make use of multiple optical wavelengths for communicating with the tag.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: May 21, 2013
    Assignee: Qinetiq Limited
    Inventors: Andrew M Scott, Keith L Lewis, Mark E McNie, Kevin M Brunson, David J Jackson, Kevin D Ridley
  • Publication number: 20120323820
    Abstract: The claimed invention relates to an adjustable derivative contract. Particularly a method and system for adjusting the derivative contract to account for time value of money due to an occurrence of a corporate event that affects the value of the derivative contract. The claimed method and system allocates distributions amongst different derivative contracts, each derivative contract representing a different economic interest of at least two shares of an underlying security. The claimed invention uses the concepts of present and future values to value derivative contracts in order to more fairly and accurately represent the interests of the various holders of such derivative contracts upon the occurrence of a corporate event affecting the value of these derivative contracts.
    Type: Application
    Filed: August 29, 2012
    Publication date: December 20, 2012
    Inventors: Peter A. BROMS, Andrew M. SCOTT
  • Publication number: 20120233093
    Abstract: The claimed invention relates to an adjustable derivative contract. Particularly a method and system for adjusting the derivative contract to account for time value of money due to an occurrence of a corporate event that affects the value of the derivative contract. The claimed method and system allocates distributions amongst different derivative contracts, each derivative contract representing a different economic interest of at least two shares of an underlying security. The claimed invention uses the concepts of present and future values to value derivative contracts in order to more fairly and accurately represent the interests of the various holders of such derivative contracts upon the occurrence of a corporate event affecting the value of these derivative contracts.
    Type: Application
    Filed: May 24, 2012
    Publication date: September 13, 2012
    Inventors: Peter A. Broms, Andrew M. Scott
  • Patent number: 8200565
    Abstract: The claimed invention relates to an adjustable derivative contract. Particularly a method and system for adjusting the derivative contract to account for time value of money due to an occurrence of a corporate event that affects the value of the derivative contract. The claimed method and system allocates distributions amongst different derivative contracts, each derivative contract representing a different economic interest of at least two shares of an underlying security. The claimed invention uses the concepts of present and future values to value derivative contracts in order to more fairly and accurately represent the interests of the various holders of such derivative contracts upon the occurrence of a corporate event affecting the value of these derivative contracts.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: June 12, 2012
    Inventors: Peter A. Broms, Andrew M. Scott
  • Patent number: 8165949
    Abstract: The claimed invention relates to an adjustable derivative contract. Particularly a method and system for adjusting the derivative contract to account for time value of money due to an occurrence of a corporate event that affects the value of the derivative contract. The claimed method and system allocates distributions amongst different derivative contracts, each derivative contract representing a different economic interest of at least two shares of an underlying security. The claimed invention uses the concepts of present and future values to value derivative contracts in order to more fairly and accurately represent the interests of the various holders of such derivative contracts upon the occurrence of a corporate event affecting the value of these derivative contracts.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: April 24, 2012
    Inventors: Peter A. Broms, Andrew M. Scott
  • Patent number: 8145551
    Abstract: The present invention relates to an adjustable equity derivative and method for allocating distributions amongst different adjustable derivative components of a security upon a corporate event effecting the underlying equity in a manner that factor in the time value of money. The present invention uses the concepts of present and future values with respect to valuing equity derivatives in order to more fairly and accurately represent the interests of the various holders of such adjustable components upon the occurrence of a corporate event affecting the value of the adjustable equity derivatives.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: March 27, 2012
    Inventors: Peter A. Broms, Andrew M. Scott
  • Patent number: 8112342
    Abstract: The present invention relates to an adjustable equity derivative and method for allocating distributions amongst different adjustable derivative components of a security upon a corporate event effecting the underlying equity in a manner that factor in the time value of money. The present invention uses the concepts of present and future values with respect to valuing equity derivatives in order to more fairly and accurately represent the interests of the various holders of such adjustable components upon the occurrence of a corporate event affecting the value of the adjustable equity derivatives.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: February 7, 2012
    Inventors: Peter A. Broms, Andrew M. Scott